Every 8-K that Kairos Pharma, Ltd. (KAPA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow KAPA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KAPA filings page.
Kairos Pharma, Ltd. (KAPA) announced that on September 14, 2026 it issued a new investor presentation that will be posted on its website and presented at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY from September 14–16, 2026. Chief Executive Officer John Yu will use this presentation to provide an update on the company’s clinical program and activities. The investor presentation is furnished as Exhibit 99.1 and is not deemed filed or incorporated by reference for Securities Act or Exchange Act purposes.
Kairos Pharma, Ltd. (KAPA) approved and implemented a 1-for-7 reverse stock split of its common stock. Stockholders had previously authorized the board to implement a reverse split in a range between 1-for-3 and 1-for-250, and the board selected a 1-for-7 ratio.
The reverse split becomes effective September 1, 2026, at the start of trading, when KAPA will trade on the NYSE American on a split-adjusted basis with new CUSIP 48301N203. Every seven shares outstanding will be reclassified into one share, with no change to the $0.001 par value or to the number of authorized common or preferred shares. Fractional positions will be rounded up to the nearest whole share. Conversion rates and exercise prices for outstanding convertible notes, warrants and equity awards will be adjusted proportionately. Kairos states the reverse split is intended to reduce the number of outstanding shares, increase the per-share trading price, and help maintain compliance with NYSE American listing requirements.
Kairos Pharma, Ltd. entered into an Agreement for the Support of Investigator / Institution Initiated Research with Bayer HealthCare Pharmaceuticals Inc. on July 16, 2026. Bayer will provide radium-223 (XOFIGO) for a study evaluating XOFIGO in combination with Kairos’ antibody ENV-105 (carotuximab) in models of prostate cancer bone metastasis.
Kairos is responsible for initiating, managing and financing the study, must obtain Bayer’s prior written approval before making material protocol changes, and will deliver final analysis, interpretation and conclusions to Bayer within 6 months after study completion. A related press release highlights ENV-105 Phase 2 data in resistant metastatic castration-resistant prostate cancer, including an 86% clinical benefit rate and median progression-free survival of more than 13 months, and describes the ENV-105 plus XOFIGO combination as targeting a $570M–$1.3B addressable global market.
Kairos Pharma, Ltd. is reporting interim safety data from an ongoing Phase 1 trial of ENV-105 (carotuximab) combined with osimertinib in patients with advanced EGFR-mutated non-small cell lung cancer. Among 13 treated patients, no serious adverse events (Grade 3 or higher) have been observed that are attributed to ENV-105, and all side effects have been manageable with standard supportive care. The study is designed to assess safety, tolerability, and a recommended Phase 2 dose.
ENV-105 is a CD105-targeting antibody intended to overcome resistance to osimertinib, the current gold-standard first-line therapy in EGFR-mutated NSCLC. The company highlights the EGFR-NSCLC market at about $10 billion, growing at a 10.5% CAGR and projected to exceed $13 billion by 2030. ENV-105 is also being evaluated in castrate-resistant prostate cancer, where a Phase 2 trial has shown median progression-free survival exceeding 13 months compared with standard care. The company includes forward-looking statements about the potential of ENV-105 across multiple tumor types.
Kairos Pharma Ltd. reported the results of its 2026 annual stockholder meeting, where 13,450,506 of 21,411,198 eligible common shares were voted, representing 62.81% participation. All four director nominees were elected for one-year terms. Stockholders ratified Weinberg & Company, P.A. as auditor for the year ending December 31, 2026. They also approved an amendment to the certificate of incorporation authorizing a reverse stock split at a ratio between 1:3 and 1:250, to be implemented at the Board’s discretion. On an advisory basis, stockholders approved executive compensation. In addition, they approved adding 5,000,000 shares to the 2023 Equity Incentive Plan and an evergreen feature allowing a 5% annual share increase for ten years.
Kairos Pharma Ltd. provides a mid-year 2026 update highlighting pipeline expansion and upcoming milestones. The company signed a term sheet with Celyn Therapeutics to acquire worldwide rights to CL-741, a Phase 1-ready c-MET kinase inhibitor for EGFR-mutated lung cancer, part of a treatment landscape valued at $16.2B in 2026. Kairos plans to start a Phase 1 study of CL-741 in EGFR-mutated lung cancer and continue Phase 1 and Phase 2 trials of its lead antibody ENV-105 in non-small cell lung and castrate-resistant prostate cancer. The company notes it is a lean operation with a low monthly burn rate and has secured more than $8 million in non-dilutive funding to support its preclinical and clinical assets.
Kairos Pharma, Ltd. furnished an investor presentation in connection with its appearance at the 2026 LD Micro Invitational XVI in Los Angeles. The presentation, available on the company’s website, is intended to update investors on its clinical program and partnering activities.
The materials are furnished, not filed, under Item 8.01 of the Exchange Act and attached as Exhibit 99.1, meaning they are not subject to Section 18 liability or automatically incorporated into other securities law filings.
Kairos Pharma, Ltd. entered into a binding term sheet to acquire 100% of the worldwide rights to CL-273, an investigational, AI-designed pan-EGFR inhibitor for EGFR-mutant non-small cell lung cancer, from Celyn Therapeutics, Inc.
As consideration, Kairos plans to issue shares so that Celyn holds 16.5% of the company on a fully diluted basis at closing, pay a $15 million milestone upon FDA NDA/BLA submission in cash and shares, and grant a 2% royalty on U.S. net revenues for the life of the applicable intellectual property. Closing is expected to be subject to shareholder approvals, absence of a material adverse effect, and any required NYSE American approval. Management highlights CL-273 as a potentially best-in-class EGFR inhibitor in an estimated $16.2 billion EGFR-mutated lung cancer market.
Kairos Pharma, Ltd. reported that it signed a letter of intent and term sheet with privately held Celyn Therapeutics to acquire worldwide rights to two oncology assets targeting non-small cell lung cancer. The drugs are CL-273, a pre-IND, reversible, wild-type-sparing pan-EGFR inhibitor, and CL-741, a Phase 1-ready, orally available type IIb c-MET kinase inhibitor.
The company highlights a large commercial opportunity: kinase inhibitors for cancer were valued at $60.7 billion in 2025, with EGFR inhibitors representing 32.5% and EGFR-mutated lung cancer treatment estimated at $16.2 billion in 2026. CL-741 targets a c-MET inhibitor market valued at more than $2 billion and projected to exceed $10 billion by 2030. Kairos believes combining EGFR and MET inhibition could address resistance in EGFR-mutant NSCLC and complement its existing antibody program ENV-105.
Kairos Pharma (KAPA) reported new equity awards and bonuses. On October 8, 2025, the Compensation Committee approved an aggregate $950,000 in restricted stock units (RSUs) under the 2023 Equity Incentive Plan for executive officers and directors, calculated at a per share price of $1.31 (the closing price on the grant date). Awards include: John S. Yu 190,840 RSUs valued at $250,000; Neil Bhomick 171,756 RSUs valued at $225,000; Ramachandran Murali 152,672 RSUs valued at $200,000; Doug Samuelson 152,672 RSUs valued at $200,000. Independent directors Hyun W. Bae, Hansoo Michael Keyoung, and Rahul Singhvi each received 19,084 RSUs valued at $25,000.
Each RSU converts into one share upon vesting on October 8, 2026, subject to continuous service, with full acceleration upon a change in control as defined in the Plan. The Committee also approved executive cash bonuses totaling $227,500 for fiscal 2024: Yu $87,500; Bhomick $50,000; Murali $40,000; Samuelson $50,000. The shares underlying these RSUs are registered on Form S-8.
Kairos Pharma, Ltd. reported that its board approved two novation agreements that move key license rights from its wholly owned subsidiary Enviro Therapeutics, Inc. directly to Kairos. Under a novation with Cedars-Sinai Medical Center, the exclusive licenses for two patent families covering DNA-based disease treatments and tumor sensitization technologies are now held by Kairos, which also assumes all related obligations and liabilities while Enviro is released from them.
A separate novation with Tracon Pharmaceuticals, Inc. transfers Enviro’s rights and obligations under a license and supply agreement for TRC105 and CD105 technologies to Kairos. The company also announced it was selected to present Phase 2 clinical data on apalutamide plus carotuximab in advanced castration-resistant prostate cancer at the European Society for Medical Oncology Congress in Berlin.
Kairos Pharma, Ltd. filed an 8-K to share that it has issued a press release announcing positive efficacy data from its ongoing Phase 2 clinical trial of ENV105 (carotuximab) in patients with metastatic castration-resistant prostate cancer (mCRPC). The company is also hosting a virtual key opinion leader event on September 18, 2025 at 5 p.m. ET / 2 p.m. PT to discuss and provide perspective on these data.
The press release is furnished as Exhibit 99.1 and the slide presentation for the event is furnished as Exhibit 99.2. This information is being furnished, not filed, under the Exchange Act, which means it is not subject to certain liability provisions and is not automatically incorporated into other securities law filings.
Kairos Pharma, Ltd. reported that it will host a premier key opinion leader (KOL) event on September 18, 2025 at 5 p.m. ET / 2 p.m. PT. The event will focus on diverse perspectives regarding interim efficacy results from a Phase 2 trial of its lead candidate, ENV105, in treating advanced prostate cancer patients. The company furnished a related press release as Exhibit 99.1, noting that this information is being provided under an “Other Events” item and is treated as furnished rather than filed under the securities laws.
Kairos Pharma, Ltd. filed a report describing a recent corporate update. On September 3, 2025, the company issued a press release announcing its participation in the World Lung Cancer Conference in Barcelona, Spain. At this meeting, Principal Investigator Dr. Karen Reckamp is scheduled to present initial Phase 1 data for the company’s drug candidate ENV105 in non-small cell lung cancer.
The conference is taking place from September 6–9, 2025 at the Fira de Barcelona Gran Via. The press release with additional details is provided as Exhibit 99.1 to the report and is being furnished rather than filed, meaning it is not incorporated into the company’s other Securities Act or Exchange Act filings by default.